NCT01811277Unknown2 期
Phase II Exploratory Study of S-1 Combined With Oxaliplatin Sequential S-1 Single-agent First-line Treatment of Unresectable Metastatic or Locally Advanced Biliary System, Periampullary Cancer and Pancreatic Cancer
Peking University1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2010年7月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Objective response rate for SOX sequential S-1
研究概览
简要总结
This is an exploratory, single-armed, open label study on the efficacy and safety of sequential S-1 therapy after SOX in unresectable metastatic or locally advanced biliary system or periampullary cancer or pancreatic cancer patients. The primary endpoint is Objective response rate and secondary endpoint is progression free survival , overall survival ,1 year survival rate and safety.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written Informed consent
- •Male or female patients >=18 years old
- •Histologically or cytologically confirmed diagnosis of adenocarcinoma
- •No previous treatment is allowed including chemotherapy, radiotherapy,immunotherapy or others.
- •In case the patient received adjuvant therapy before, enrollment is allowed if the adjuvant therapy does not contain L-OHP or S-1 and at the same time, the last day of chemotherapy is ≥180 days before screening.
- •Target lesion more than 1cm in diameter by enhanced CT or MRI 21 days before enrollment
- •The laboratory parameter meets the following criteria 7 days before enrollment
- •Hemoglobin ≥90g/L
- •Absolute neutrophil count≥1.5×10^9/L, platelets 100×10^9/L；
- •ALT and AST≤2.5 ULN(in case of the patients with liver metastasis,ALT and AST≤5.0 ULN)
- •ALP ≤2.5 ULN (in case of the patients with liver metastasis,≤5.0 ULN)
- •Total Serum bilirubin ≤1.5 ULN
- •Serum creatinine ≤1.0 ULN
- •serum albumin(ALB)≥30g/L；
- •can tolerate oral drug administration；
- •Estimated survival ≥90 days
- •Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days of enrollment and must be willing to use adequate methods of contraception during the study and for 30 days after last study durg administration.
排除标准
- •Known sensitivity to 5-HT3 antagonist and hypersensitivity to the other treatment agents including irinotecan, cisplatin and octreotide lar
- •Any participation in trials simultaneously or 4 weeks before screening.
- •15 days prior to enrollment, received a blood transfusion, blood products and hematopoietic growth factors such as G-CSF.
- •Undergone major surgery ≤ 4 weeks prior to starting study drug or who have not recovered from side effects of such surgery.
- •Uncontrolled severe diarrhea
- •Uncontrolled active infection (fever ≥38 degrees due to infection)
- •S-1 oral drug administration difficulty due to difficulty swallowing, complete or incomplete digestive tract obstruction, gastrointestinal active bleeding, perforation;
- •severe hepatopathy including active hepatitis and hepatic cirrhosis, renal dysfunction, severe pulmonary diseases including interstitial pneumonia, pulmonary fibrosis and severe pulmonary emphysema, uncontrolled diabetes, hypertension and other chronic systematic diseases.
- •Chronic treatment with steroids.(In case of the patients with short-term use of steroids, the enrollment is permitted if the administration is stopped 2 weeks before screening.)
- •confirmed or suspected CNS metastasis
- •the history of peripheral nervous system impairment, obvious mental disorder or CNS impairment
- •clinically significant heart disease, including congestive heart failure, symptomatic coronal heart disease, arrythmia uncontrolled by medication and acute myocardial infarction or cardiac insufficiency within 6 months before screening
- •Drainage of pleural effusion, peritoneal effusion and pericardial effusion
- •pregnant women or women in lactation period
- •Fertile male or women of child-bearing potential refuse to take highly effective methods of birth control
- •Incidence of other second primary malignant tumors within 5 years, except for cured basal cell carcinoma and cervical carcinoma in situ.
- •patients of legal incapacity or who have the potential of influence the whole trial due to medical or ethic reasons.
- •Other patients who are not eligible to the trial under investigators' discretion
研究组 & 干预措施
SOX sequential S-1
Experimental
4-6 cycles of SOX followed by S-1 monotherapy until disease progression
干预措施: SOX sequential S-1 (Drug)
结局指标
主要结局
Objective response rate for SOX sequential S-1
时间窗: 1 years
The primary endpoint is objective response rate,which equals CR+PR.
次要结局
- Overall Survival(2 years)
- progression free survival(1 year)
- 1 year survival rate(1 year)
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability(2 years)
研究者
Shen Lin
Head of GI Cancer department
Peking University
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
A Phase I Study of S-1 Plus Irinotecan and Oxaliplatin in Advanced Gastrointestinal MalignancyColorectal NeoplasmGastric NeoplasmSecondaryNCT00506207National Cancer Center, Korea23
Unknown
2 期
Study of Continuous or Intermittent S-1 Combined With Oxaliplatin in Recurrent or Metastatic Gastric CarcinomaStomach NeoplasmsNCT00515190National Cancer Center, Korea198
终止
1 期
A Phase I/II Study of the Safety and Efficacy of Sernova's Cell PouchTM for Therapeutic Islet TransplantationType I DiabetesNCT01652911University of Alberta3
已完成
2 期
Randomized phase II study comparing S-1 plus oxaliplatin with S-1 monotherapy for elderly patients with advanced gastric cancer.(WJOG8315G)advanced gastric cancer.JPRN-UMIN000020864West Japan Oncology Group160
进行中（未招募）
2 期
Randomized phase II study comparing S-1 plus oxaliplatin with S-1 monotherapy for elderly patients with advanced gastric cancer.(WJOG8315G)Advanced gastric cancer.JPRN-jRCTs041190004Makiyama Akitaka160